Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of pirtobrutinib versus investigator's choice in previously treated CLL/SLL after prior BTK inhibitor
MOH_2021-09-14_010245Phase 3Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib, idelalisib, rituximab and bendamustine in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (4 arms), sponsored by Loxo Oncology. Started Aug 2021; status: active, not recruiting.
02
Drugs
pirtobrutinibidelalisibrituximabbendamustine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2021-09-14_010245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-14_010245.